A
Athira Pharma, Inc. (ATHA)
NCM – Real vaqt narxi. Valyuta: USD
6.75
-0.44 (-6.12%)
Yopilishda: Jan 9, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.75
-0.44 (-6.12%)
Yopilishda: Jan 9, 2026, 4:00 PM EDT
Athira Pharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, neyronlarning sog'lig'ini tiklash va neyrodegeneratsiyani sekinlashtirish uchun kichik molekulalarni ishlab chiqishga qaratilgan. Mahsulotlar liniyasi ALS (amyotrophic lateral sclerosis)ni davolash uchun ATH-1105ni o'z ichiga oladi, bu 1-bosqich klinik sinovda; neyrodegenerativ kasalliklarni davolash uchun ATH-1020, bu 1-bosqich klinik sinovda, shuningdek, preklinik bosqichda bo'lgan dastlabki birikmalar. Kompaniya ilgari M3 Biotechnology, Inc. nomi bilan tanilgan va 2019 yil aprel oyida Athira Pharma, Inc. nomini o'zgartirgan. Athira Pharma, Inc. 2011 yilda tashkil etilgan va shtab-kvartirasi Vashingtonning Bothell shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Dr. Mark J. Litton M.B.A., Ph.D. | President, CEO & Director |
| Mr. Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Mr. Robert Renninger | Chief Financial Officer |
| Ms. Julie Rathbun | Head of Investor Relations |
There is no data to display